stockrow
Friday 6 November 2026
Export BHVN’s income statement to Excel — free account
Biohaven Ltd.
BHVN Healthcare Biotechnology
- EPS
- +47.8%
- Free cash flow
- +26.6%
- Total debt
- −1.48%
Quarter to September 2026, against a year earlier
14.41
0.51
+3.67%
Follow BHVN
Alert me
Biohaven Ltd. (BHVN) Current ratio
Biohaven Ltd.'s current ratio at the end of the quarter to 30 September 2026 was 3.1×, down 0.1× from fiscal 2025 (3.2×). Over the past ten years it has ranged from 2.2× (fiscal 2020) to 14.5× (fiscal 2017); the current reading is higher than 36% of that period. That is below the Biotechnology industry median of 4.9× and in line with the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 3.2× | (9.00%) |
| FY2024 | 3.5× | (56.27%) |
| FY2023 | 8.0× | 22.43% |
| FY2022 | 6.5× | 188.36% |
| FY2021 | 2.3× | 4.03% |
| FY2020 | 2.2× | (56.19%) |
| FY2019 | 5.0× | (64.42%) |
| FY2018 | 13.9× | (3.81%) |
| FY2017 | 14.5× | 378.94% |
| FY2016 | 3.0× | (47.24%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 3.1× | (35.53%) |
| Jun 2026 | 4.7× | (36.09%) |
| Mar 2026 | 7.4× | 133.09% |
| Dec 2025 | 3.2× | 10.96% |
| 37 more quarters | Free account |
Against its own ten years
Low 2.2×
High 14.5×
Ten-year median
5.0×
Current reading's percentile
36
Current ratio against peers
| Company | Current ratio |
|---|---|
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 32.8× |
| PVLA Palvella Therapeutics, Inc. compare | 21.2× |
| IMNM Immunome, Inc. compare | 15.1× |
| CLDX Celldex Therapeutics, Inc. compare | 11.8× |
| VERA Vera Therapeutics, Inc. compare | 10.9× |
| AUPH Aurinia Pharmaceuticals Inc compare | 6.1× |
| ADMA ADMA Biologics Inc compare | 6.0× |
| VCEL Vericel Corporation compare | 5.1× |
| BHVN Biohaven Ltd. | 3.1× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)